Accent Therapeutics Showcases Findings of ATX-295 at Upcoming ASCO Annual Meeting
Accent Therapeutics Showcases Findings of ATX-295 at Upcoming ASCO Annual Meeting
Accent Therapeutics, a biopharmaceutical company at the forefront of small molecule precision cancer therapies, has announced an exciting milestone in its research journey. The company is set to present a Trial in Progress poster that outlines the ongoing Phase 1/2 clinical study of ATX-295 at the prestigious 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO). This event will take place from May 29 to June 2 in Chicago, Illinois.
Understanding ATX-295 and Its Potential
ATX-295 is being heralded as a potentially best-in-class oral inhibitor of KIF18A, a vital mitotic kinesin motor protein crucial for cell division, especially in tumors exhibiting chromosomal instability. Given that a substantial number of solid tumors, including high-grade serous ovarian cancer (HGSOC) and squamous non-small cell lung cancer (sqNSCLC), present significant challenges in treatment due to their unique genetic makeup, ATX-295 offers a differentiated approach aimed at exploiting these vulnerabilities.
Dr. Jason Sager, Chief Medical Officer at Accent Therapeutics, expressed the company's excitement about the clinical study, stating, "KIF18A inhibition provides a unique pathway to address a fundamental vulnerability in chromosomally instable tumors. Our extensive preclinical evidence supports the potential of ATX-295, and we are committed to moving forward with this rigorous clinical program to meet significant patient needs."
Insights from the Trial in Progress Poster
The poster will elaborate on the study's design and the scientific rationale underpinning this groundbreaking research. The Phase 1/2 study, noted as NCT06799065, is actively recruiting patients who are dealing with locally advanced or metastatic solid tumors. It includes an initial dose-escalation phase, which will help determine the recommended Phase 2 dose (RP2D), followed by a dose-expansion phase aimed at assessing preliminary antitumor activity.
This multifaceted study will focus on several primary and secondary endpoints, including:
- - Safety and Tolerability: Evaluating how well ATX-295 is tolerated in patients.
- - Pharmacokinetics (PK): Understanding how the drug moves through the body.
- - Pharmacodynamics (PD) effects: Assessing how ATX-295 affects cancer cells.
- - Preliminary Efficacy: Looking at early signs of its potential effectiveness against tumors.
Presentation Details
- - Poster Title: Trial in Progress - A Phase 1/2 First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients with Advanced or Metastatic Solid Tumors, Including Ovarian Cancer.
- - Abstract Number: TPS3167.
- - Session Title: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology.
- - Session Date and Time: Saturday, May 30, 1:30 – 4:30 PM CDT.
- - Location: Hall A – Posters and Exhibits.
- - Presenter: Dr. Judy S. Wang, affiliated with Florida Cancer Specialists/Sarah Cannon Research Institute.
Following the meeting, the poster will be accessible on the Accent Therapeutics website, providing further insights into this promising clinical trial.
Conclusion
Accent Therapeutics is pioneering innovative treatment avenues in oncology, and the ongoing research surrounding ATX-295 could illuminate a path towards new therapeutic options for patients facing advanced solid tumors. As the Phase 1/2 study progresses, the scientific community and oncology patients alike will be keenly awaiting the results from this ambitious clinical endeavor. For more information on the company's efforts to transform cancer treatment, visit Accent Therapeutics or their LinkedIn page.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.